Accountability Lab Community of Practice

Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout.

Was this article helpful?
YesNo

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll to Top